参考文献/References:
[1] Saeedi P,Petersohn I,Salpea P,et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:results from the International Diabetes Federation Diabetes Atlas,9th edition[J].Diabetes Res Clin Pract,2019,157:107843.DOI:10.1016/j.diabres.2019.107843.
[2] 陆菊明.2型糖尿病治疗的现状与挑战——肠促胰岛素治疗的前景[J].国际内分泌代谢杂志,2009,29(3):171-174.DOI:10.3760/cma.j.issn.1673-4157.2009.03.007.
[3] Knerr PJ,Finan B,Gelfanov V,et al.Optimization of peptide-based polyagonists for treatment of diabetes and obesity[J].Bioorg Med Chem,2018,26(10):2873-2881.DOI:10.1016/j.bmc.2017.10.047.
[4] Bailey CJ.GIP analogues and the treatment of obesity-diabetes[J].Peptides,2020,125:170202.DOI:10.1016/j.peptides.2019.170202.
[5] Coskun T,Sloop KW,Loghin C,et al.LY3298176,a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus:from discovery to clinical proof of concept[J].Mol Metab,2018,18:3-14.DOI:10.1016/j.molmet.2018.09.009.
[6] Ohwaki K,Furihata K,Mimura H,et al.Effect of Tirzepatide,a dual GIP and GLP-1 receptor agonist,on glycemic control and body weight in Japanese patients with T2DM[J].Diabetes,2019,68(Supplement 1)1024-P.DOI:10.2337/db19-1024-P.
[7] Urva S,Quinlan T,Landry J,et al.Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist Tirzepatide[J].Clin Pharmacokinet,2021,60(8):1049-1059.DOI:10.1007/s40262-021-01012-2.
[8] Frias JP,Nauck MA,Van J,et al.Efficacy and safety of LY3298176,a novel dual GIP and GLP-1 receptor agonist,in patients with type 2 diabetes:a randomised,placebo-controlled and active comparator-controlled phase 2 trial[J].Lancet,2018,392(10160):2180-2193.DOI:10.1016/S0140-6736(18)32260-8.
[9] Frias JP,Nauck MA,Van J,et al.Efficacy and tolerability of tirzepatide,a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes:a 12-week,randomized,double-blind,placebo-controlled study to evaluate different dose-escalation regimens[J].Diabetes Obes Metab,2020,22(6):938-946.DOI:10.1111/dom.13979.
[10] Holst JJ.Incretin therapy for diabetes mellitus type 2[J].Curr Opin Endocrinol Diabetes Obes,2020,27(1):2-10.DOI:10.1097/MED.0000000000000516.
[11] El K,Campbell JE.The role of GIP in α-cells and glucagon secretion[J].Peptides,2020,125:170213.DOI:10.1016/j.peptides.2019.170213.
[12] Højberg PV,Vilsbøll T,Rabøl R,et al.Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes[J].Diabetologia,2009,52(2):199-207.DOI:10.1007/s00125-008-1195-5.
[13] Mathiesen DS,Bagger JI,Bergmann NC,et al.The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-a review[J].Int J Mol Sci,2019,20(17):4092.DOI:10.3390/ijms20174092.
[14] Thomas MK,Nikooienejad A,Bray R,et al.Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes[J].J Clin Endocrinol Metab,2021,106(2):388-396.DOI:10.1210/clinem/dgaa863.
[15] Samms RJ,Coghlan MP,Sloop KW.How may GIP enhance the therapeutic efficacy of GLP-1[J].Trends Endocrinol Metab,2020,31(6):410-421.DOI:10.1016/j.tem.2020.02.006.
[16] 姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,34(1):36-39.DOI:10.3760/cma.j.issn.1673-4157.2014.01.010.
[17] Adriaenssens AE,Biggs EK,Darwish T,et al.Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake[J].Cell Metab,2019,30(5):987-996.e6.DOI:10.1016/j.cmet.2019.07.013.
[18] Okereke OI,Selkoe DJ,Pollak MN,et al.A profile of impaired insulin degradation in relation to late-life cognitive decline:a preliminary investigation[J].Int J Geriatr Psychiatry,2009,24(2):177-182.DOI:10.1002/gps.2089.
[19] Hölscher C.Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models[J].Neuropharmacology,2018,136(Pt B):251-259.DOI:10.1016/j.neuropharm.2018.01.040.
[20] Chen J,Zhu Y,Zheng Q,et al.Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis:a meta-analysis[J].Hepatol Res,2014,44(8):854-862.DOI:10.1111/hepr.12197.
[21] Luo Y,Oseini A,Gagnon R,et al.An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis[J].Sci Rep,2018,8(1):12414.DOI:10.1038/s41598-018-30457-y.
[22] Hartman ML,Sanyal AJ,Loomba R,et al.Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J].Diabetes Care,2020,43(6):1352-1355.DOI:10.2337/dc19-1892.
相似文献/References:
[1]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(06):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[2]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(06):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[3]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(06):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(06):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[6]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(06):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[7]田甜,沈山梅.肠促胰素与骨质疏松[J].国际内分泌代谢杂志,2016,36(05):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
Tian Tian,Shen Shanmei.Incretin and osteoporosis[J].International Journal of Endocrinology and Metabolism,2016,36(06):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
[8]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(06):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[9]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(06):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[10]王永 乐岭.GLP-1对血管重构中血管平滑肌细胞的影响[J].国际内分泌代谢杂志,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
Wang Yong,Yue Ling.Effects of GLP-1 on vascular smooth muscle cells in vascular remodeling[J].International Journal of Endocrinology and Metabolism,2018,38(06):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]